An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Status:
Recruiting
Trial end date:
2025-12-04
Target enrollment:
Participant gender:
Summary
The goal of this Phase 2 Open-Label Extension (OLE) is to evaluate long-term safety,
tolerability, and efficacy of XPro1595 on measures of cognition, function and brain quality
in individuals with mild Alzheimer's Disease or MCI with biomarkers of inflammation.